Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2016, Article ID 2672740, 15 pages
http://dx.doi.org/10.1155/2016/2672740
Review Article

Hybrid Nanomaterials Based on Iron Oxide Nanoparticles and Mesoporous Silica Nanoparticles: Overcoming Challenges in Current Cancer Treatments

1Department of Science and Technology, Inter American University of Puerto Rico, Ponce Campus, Ponce, PR 00716, USA
2Department of Chemistry, The University of North Carolina at Charlotte, Charlotte, NC 28223, USA
3The Center for Biomedical Engineering and Science, The University of North Carolina at Charlotte, Charlotte, NC 28223, USA

Received 26 February 2016; Accepted 11 April 2016

Academic Editor: Dennis Douroumis

Copyright © 2016 Merlis P. Alvarez-Berríos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Cancer Facts & Figures 2016, American Cancer Society, Atlanta, Ga, USA, 2016.
  2. E. D. S. Tolentino, B. S. Centurion, L. H. C. Ferreira, A. P. de Souza, J. H. Damante, and I. R. F. Rubira-Bullen, “Oral adverse effects of head and neck radiotherapy: literature review and suggestion of a clinical oral care guideline for irradiated patients,” Journal of Applied Oral Science, vol. 19, no. 5, pp. 448–454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. B. A. Chabner and T. G. Roberts Jr., “Timeline: chemotherapy and the war on cancer,” Nature Reviews Cancer, vol. 5, no. 1, pp. 65–72, 2005. View at Google Scholar
  4. A. Nguyen, L. Ho, and Y. Wan, “Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer,” Frontiers in Oncology, vol. 4, article 145, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. C. B. Matsen and L. A. Neumayer, “Breast cancer: a review for the general surgeon,” JAMA Surgery, vol. 148, no. 10, pp. 971–979, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. F. Leber and T. Efferth, “Molecular principles of cancer invasion and metastasis (review),” International Journal of Oncology, vol. 34, no. 4, pp. 881–895, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. Sailor and J.-H. Park, “Hybrid nanoparticles for detection and treatment of cancer,” Advanced Materials, vol. 24, no. 28, pp. 3779–3802, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. L. Vivero-Escoto and Y.-T. Huang, “Inorganic-organic hybrid nanomaterials for therapeutic and diagnostic imaging applications,” International Journal of Molecular Sciences, vol. 12, no. 6, pp. 3888–3927, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Hao, X. Hu, C. Zhang et al., “Hybrid mesoporous silica-based drug carrier nanostructures with improved degradability by hydroxyapatite,” ACS Nano, vol. 9, no. 10, pp. 9614–9625, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Torres-Lugo and C. Rinaldi, “Thermal potentiation of chemotherapy by magnetic nanoparticles,” Nanomedicine, vol. 8, no. 10, pp. 1689–1707, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. V. P. Torchilin, “Passive and active drug targeting: drug delivery to tumors as an example,” Handbook of Experimental Pharmacology, no. 197, pp. 3–53, 2010. View at Google Scholar
  12. I.-P. Huang, S.-P. Sun, S.-H. Cheng et al., “Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance,” Molecular Cancer Therapeutics, vol. 10, no. 5, pp. 761–769, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Xie, F. Li, H. Zhang et al., “EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery,” European Journal of Pharmaceutical Sciences, vol. 83, pp. 28–35, 2016. View at Publisher · View at Google Scholar
  14. Y. Wang, Q. Zhao, N. Han et al., “Mesoporous silica nanoparticles in drug delivery and biomedical applications,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 11, no. 2, pp. 313–327, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Zhang, Y. Shi, Y. Chen, J. Ye, X. Sha, and X. Fang, “Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors,” Biomaterials, vol. 32, no. 11, pp. 2894–2906, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. P. Alvarez-Berríos, A. Castillo, C. Rinaldi, and M. Torres-Lugo, “Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines,” International Journal of Nanomedicine, vol. 9, pp. 145–153, 2014. View at Google Scholar
  17. M. P. Alvarez-Berrios, A. Castillo, F. Merida, J. Mendez, C. Rinaldi, and M. Torres-Lugo, “Enhanced proteotoxic stress: one of the contributors for hyperthermic potentiation of the proteasome inhibitor bortezomib using magnetic nanoparticles,” Biomaterials Science, vol. 3, no. 2, pp. 391–400, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. M. P. Alvarez-Berríos, A. Castillo, J. Mendéz, O. Soto, C. Rinaldi, and M. Torres-Lugo, “Hyperthermic potentiation of cisplatin by magnetic nanoparticle heaters is correlated with an increase in cell membrane fluidity,” International Journal of Nanomedicine, vol. 8, pp. 1003–1013, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Marincek, “Diagnostic improvement in MRI of gynecological neoplasms,” Journal Belge de Radiologie, vol. 79, no. 1, pp. 13–17, 1996. View at Google Scholar · View at Scopus
  20. P. Reimer and T. Balzer, “Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications,” European Radiology, vol. 13, no. 6, pp. 1266–1276, 2003. View at Google Scholar · View at Scopus
  21. S.-H. Hu, Y.-Y. Chen, T.-C. Liu, T.-H. Tung, D.-M. Liu, and S.-Y. Chen, “Remotely nano-rupturable yolk/shell capsules for magnetically-triggered drug release,” Chemical Communications, vol. 47, no. 6, pp. 1776–1778, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Amstad and E. Reimhult, “Nanoparticle actuated hollow drug delivery vehicles,” Nanomedicine, vol. 7, no. 1, pp. 145–164, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Hu, S. Ma, H. Li et al., “Effect of magnetic fluid hyperthermia on lung cancer nodules in a murine model,” Oncology Letters, vol. 2, no. 6, pp. 1161–1164, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Laurent, S. Dutz, U. O. Häfeli, and M. Mahmoudi, “Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles,” Advances in Colloid and Interface Science, vol. 166, no. 1-2, pp. 8–23, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. E. H. Frei, “Magnetism and medicine,” Journal of Applied Physics, vol. 40, no. 3, pp. 955–957, 1969. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Estelrich, E. Escribano, J. Queralt, and M. A. Busquets, “Iron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery,” International Journal of Molecular Sciences, vol. 16, no. 4, pp. 8070–8101, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. A. S. Lübbe, C. Alexiou, and C. Bergemann, “Clinical applications of magnetic drug targeting,” Journal of Surgical Research, vol. 95, no. 2, pp. 200–206, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Polyak and G. Friedman, “Magnetic targeting for site-specific drug delivery: applications and clinical potential,” Expert Opinion on Drug Delivery, vol. 6, no. 1, pp. 53–70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. K. J. Widder, A. E. Senyel, and G. D. Scarpelli, “Magnetic microspheres: a model system of site specific drug delivery in vivo,” Proceedings of the Society for Experimental Biology and Medicine, vol. 158, no. 2, pp. 141–146, 1978. View at Google Scholar
  30. S. Lyer, R. Tietze, R. Jurgons et al., “Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles—a pilot study,” Anticancer Research, vol. 30, no. 5, pp. 1553–1557, 2010. View at Google Scholar · View at Scopus
  31. X. Thomas, M. Elhamri, Y. Chelghoum et al., “Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial,” Annals of Hematology, vol. 84, no. 6, pp. 376–382, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Alexiou, W. Arnold, R. J. Klein et al., “Locoregional cancer treatment with magnetic drug targeting,” Cancer Research, vol. 60, no. 23, pp. 6641–6648, 2000. View at Google Scholar · View at Scopus
  33. C. Alexiou, R. Jurgons, R. J. Schmid et al., “Magnetic drug targeting—biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment,” Journal of Drug Targeting, vol. 11, no. 3, pp. 139–149, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Tietze, S. Lyer, S. Dürr et al., “Efficient drug-delivery using magnetic nanoparticles—biodistribution and therapeutic effects in tumour bearing rabbits,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 9, no. 7, pp. 961–971, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. T. M. Mekhail and M. Markman, “Paclitaxel in cancer therapy,” Expert Opinion on Pharmacotherapy, vol. 3, no. 6, pp. 755–766, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Q. Zhang, Z. R. Zhang, H. Yang, Q. Y. Tan, S. R. Qin, and X. L. Qiu, “Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies,” Pharmaceutical Research, vol. 22, no. 4, pp. 573–583, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Béalle, R. Di Corato, J. Kolosnjaj-Tabi et al., “Ultra magnetic liposomes for MR imaging, targeting, and hyperthermia,” Langmuir, vol. 28, no. 32, pp. 11834–11842, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Y. Joh, L. Sun, M. Stangl et al., “Selective targeting of brain tumors with gold nanoparticle-induced radiosensitization,” PLoS ONE, vol. 8, no. 4, Article ID e62425, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. H.-L. Liu, M.-Y. Hua, H.-W. Yang et al., “Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 34, pp. 15205–15210, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Chertok, A. E. David, and V. C. Yang, “Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration,” Biomaterials, vol. 31, no. 24, pp. 6317–6324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. A. S. Lubbe, C. Bergemann, H. Riess et al., “Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors,” Cancer Research, vol. 56, no. 20, pp. 4686–4693, 1996. View at Google Scholar
  42. Z. Saiyed, S. Telang, and C. Ramchand, “Application of magnetic techniques in the field of drug discovery and biomedicine,” Biomagnetic Research and Technology, vol. 1, no. 1, article 2, 2003. View at Google Scholar
  43. M. W. Wilson, R. K. Kerlan Jr., N. A. Fidelman et al., “Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite—initial experience with four patients,” Radiology, vol. 230, no. 1, pp. 287–293, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. R. D. Issels, “Hyperthermia adds to chemotherapy,” European Journal of Cancer, vol. 44, no. 17, pp. 2546–2554, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. M. H. Falk and R. D. Issels, “Hyperthermia in oncology,” International Journal of Hyperthermia, vol. 17, no. 1, pp. 1–18, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Likhitkar and A. K. Bajpai, “Magnetically controlled release of cisplatin from superparamagnetic starch nanoparticles,” Carbohydrate Polymers, vol. 87, no. 1, pp. 300–308, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Rajeswaran, A. Trojan, B. Burnand, and M. Giannelli, “Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials,” Lung Cancer, vol. 59, no. 1, pp. 1–11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Babincová, V. Altanerová, C. Altaner, C. Bergemann, and P. Babinec, “In vitro analysis of cisplatin functionalized magnetic nanoparticles in combined cancer chemotherapy and electromagnetic hyperthermia,” IEEE Transactions on NanoBioscience, vol. 7, no. 1, pp. 15–19, 2008. View at Publisher · View at Google Scholar
  49. A. J. Wagstaff, S. D. Brown, M. R. Holden et al., “Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting with external magnetic fields,” Inorganica Chimica Acta, vol. 393, pp. 328–333, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Taylor, Y. Krupskaya, K. Krämer et al., “Cisplatin-loaded carbon-encapsulated iron nanoparticles and their in vitro effects in magnetic fluid hyperthermia,” Carbon, vol. 48, no. 8, pp. 2327–2334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. J. S. Lee, H. L. Rodríguez-Luccioni, J. Méndez et al., “Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum,” Journal of Nanoscience and Nanotechnology, vol. 11, no. 5, pp. 4153–4157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. A. A. Petryk, A. J. Giustini, R. E. Gottesman, P. A. Kaufman, and P. J. Hoopes, “Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment,” International Journal of Hyperthermia, vol. 29, no. 8, pp. 845–851, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. N. A. Brusentsov, V. A. Polyanskii, Y. A. Pirogov et al., “Antitumor effects of the combination of magnetohydrodynamic thermochemotherapy and magnetic resonance tomography,” Pharmaceutical Chemistry Journal, vol. 44, no. 6, pp. 291–295, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Ito, H. Saito, K. Mitobe et al., “Inhibition of heat shock protein 90 sensitizes melanoma cells to thermosensitive ferromagnetic particle-mediated hyperthermia with low Curie temperature,” Cancer Science, vol. 100, no. 3, pp. 558–564, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Amstad, J. Kohlbrecher, E. Müller, T. Schweizer, M. Textor, and E. Reimhult, “Triggered release from liposomes through magnetic actuation of iron oxide nanoparticle containing membranes,” Nano Letters, vol. 11, no. 4, pp. 1664–1670, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. Ren, H. Zhang, B. Chen et al., “Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance,” International Journal of Nanomedicine, vol. 7, pp. 2261–2269, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. B. Piperdi, Y.-H. Ling, L. Liebes, F. Muggia, and R. Perez-Soler, “Bortezomib: understanding the mechanism of action,” Molecular Cancer Therapeutics, vol. 10, no. 11, pp. 2029–2030, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Neznanov, A. P. Komarov, L. Neznanova, P. Stanhope-Baker, and A. V. Gudkov, “Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib,” Oncotarget, vol. 2, no. 3, pp. 209–221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Johannsen, U. Gneveckow, L. Eckelt et al., “Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique,” International Journal of Hyperthermia, vol. 21, no. 7, pp. 637–647, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Johannsen, B. Thiesen, P. Wust, and A. Jordan, “Magnetic nanoparticle hyperthermia for prostate cancer,” International Journal of Hyperthermia, vol. 26, no. 8, pp. 790–795, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Schroeder, D. A. Heller, M. M. Winslow et al., “Treating metastatic cancer with nanotechnology,” Nature Reviews Cancer, vol. 12, no. 1, pp. 39–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. O. L. Gobbo, K. Sjaastad, M. W. Radomski, Y. Volkov, and A. Prina-Mello, “Magnetic nanoparticles in cancer theranostics,” Theranostics, vol. 5, no. 11, pp. 1249–1263, 2015. View at Publisher · View at Google Scholar
  63. O. Will, S. Purkayastha, C. Chan et al., “Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis,” The Lancet Oncology, vol. 7, no. 1, pp. 52–60, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. T. Harada, N. Tanigawa, M. Matsuki, T. Nohara, and I. Narabayashi, “Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging,” European Journal of Radiology, vol. 63, no. 3, pp. 401–407, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. M. G. Harisinghani, J. Barentsz, P. F. Hahn et al., “Noninvasive detection of clinically occult lymph-node metastases in prostate cancer,” The New England Journal of Medicine, vol. 348, no. 25, pp. 2491–2499, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Wu, Y. Cao, C. Liao, J. Huang, and F. Gao, “Diagnostic performance of USPIO-enhanced MRI for lymph-node metastases in different body regions: a meta-analysis,” European Journal of Radiology, vol. 80, no. 2, pp. 582–589, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Leuschner, C. S. S. R. Kumar, W. Hansel, W. Soboyejo, J. Zhou, and J. Hormes, “LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases,” Breast Cancer Research and Treatment, vol. 99, no. 2, pp. 163–176, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Vu-Quang, M. Muthiah, H. J. Lee et al., “Immune cell-specific delivery of beta-glucan-coated iron oxide nanoparticles for diagnosing liver metastasis by MR imaging,” Carbohydrate Polymers, vol. 87, no. 2, pp. 1159–1168, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. W. Liu, L. Nie, F. Li et al., “Folic acid conjugated magnetic iron oxide nanoparticles for nondestructive separation and detection of ovarian cancer cells from whole blood,” Biomaterials Science, vol. 4, no. 1, pp. 159–166, 2016. View at Publisher · View at Google Scholar
  70. I. I. Slowing, J. L. Vivero-Escoto, C.-W. Wu, and V. S.-Y. Lin, “Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers,” Advanced Drug Delivery Reviews, vol. 60, no. 11, pp. 1278–1288, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. Kuthati, P.-J. Sung, C.-F. Weng, C.-Y. Mou, and C.-H. Lee, “Functionalization of mesoporous silica nanoparticles for targeting, biocompatibility, combined cancer therapies and theragnosis,” Journal of Nanoscience and Nanotechnology, vol. 13, no. 4, pp. 2399–2430, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Chen, H. Chen, S. Zhang et al., “Multifunctional mesoporous nanoellipsoids for biological bimodal imaging and magnetically targeted delivery of anticancer drugs,” Advanced Functional Materials, vol. 21, no. 2, pp. 270–278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. W. Zhao, H. Chen, Y. Li, A. Li, M. Lang, and J. Shi, “Uniform rattle-type hollow magnetic mesoporous spheres as drug delivery carriers and their sustained-release property,” Advanced Functional Materials, vol. 18, no. 18, pp. 2780–2788, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Tu, Y. Lin, H. Lin et al., “In vitro studies of functionalized mesoporous silica nanoparticles for photodynamic therapy,” Advanced Materials, vol. 21, no. 2, pp. 172–177, 2009. View at Publisher · View at Google Scholar
  75. J. E. Lee, N. Lee, H. Kim et al., “Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery,” Journal of the American Chemical Society, vol. 132, no. 2, pp. 552–557, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. C. Caltagirone, A. Bettoschi, A. Garau, and R. Montis, “Silica-based nanoparticles: a versatile tool for the development of efficient imaging agents,” Chemical Society Reviews, vol. 44, no. 14, pp. 4645–4671, 2015. View at Publisher · View at Google Scholar · View at Scopus
  77. J. L. Vivero-Escoto, R. C. Huxford-Phillips, and W. Lin, “Silica-based nanoprobes for biomedical imaging and theranostic applications,” Chemical Society Reviews, vol. 41, no. 7, pp. 2673–2685, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. N.-T. Chen, S.-H. Cheng, J. S. Souris, C.-T. Chen, C.-Y. Mou, and L.-W. Lo, “Theranostic applications of mesoporous silica nanoparticles and their organic/inorganic hybrids,” Journal of Materials Chemistry B, vol. 1, no. 25, pp. 3128–3135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. J. L. Vivero-Escoto, I. I. Slowing, V. S.-Y. Lin, and B. G. Trewyn, “Mesoporous silica nanoparticles for intracellular controlled drug delivery,” Small, vol. 6, no. 18, pp. 1952–1967, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. L. Kelland, “The resurgence of platinum-based cancer chemotherapy,” Nature Reviews Cancer, vol. 7, no. 8, pp. 573–584, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Markman, “Toxicities of the platinum antineoplastic agents,” Expert Opinion on Drug Safety, vol. 2, no. 6, pp. 597–607, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Reedijk, “New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 3611–3616, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. P. R. Brock, K. R. Knight, D. R. Freyer et al., “Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale,” Journal of Clinical Oncology, vol. 30, no. 19, pp. 2408–2417, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. N. Bardeesy and R. A. DePinho, “Pancreatic cancer biology and genetics,” Nature Reviews Cancer, vol. 2, no. 12, pp. 897–909, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Stathis and M. J. Moore, “Advanced pancreatic carcinoma: current treatment and future challenges,” Nature Reviews Clinical Oncology, vol. 7, no. 3, pp. 163–172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. M. K. Gurka, D. Pender, P. Chuong et al., “Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography,” Journal of Controlled Release, 2016. View at Publisher · View at Google Scholar
  87. Q. Zhang, K. G. Neoh, L. Xu et al., “Functionalized mesoporous silica nanoparticles with mucoadhesive and sustained drug release properties for potential bladder cancer therapy,” Langmuir, vol. 30, no. 21, pp. 6151–6161, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Jambhrunkar, S. Karmakar, A. Popat, M. Yu, and C. Yu, “Mesoporous silica nanoparticles enhance the cytotoxicity of curcumin,” RSC Advances, vol. 4, no. 2, pp. 709–712, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. E. Niemelä, D. Desai, Y. Nkizinkiko, J. E. Eriksson, and J. M. Rosenholm, “Sugar-decorated mesoporous silica nanoparticles as delivery vehicles for the poorly soluble drug celastrol enables targeted induction of apoptosis in cancer cells,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 96, pp. 11–21, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. K. Wang, H. Yao, Y. Meng, Y. Wang, X. Yan, and R. Huang, “Specific aptamer-conjugated mesoporous silica-carbon nanoparticles for HER2-targeted chemo-photothermal combined therapy,” Acta Biomaterialia, vol. 16, no. 1, pp. 196–205, 2015. View at Publisher · View at Google Scholar · View at Scopus
  91. X. Hu, M. Wang, F. Miao, J. Ma, H. Shen, and N. Jia, “Regulation of multifunctional mesoporous core-shell nanoparticles with luminescence and magnetic properties for biomedical applications,” Journal of Materials Chemistry B, vol. 2, no. 16, pp. 2265–2275, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. Y. Chen, K. Ai, J. Liu, G. Sun, Q. Yin, and L. Lu, “Multifunctional envelope-type mesoporous silica nanoparticles for pH-responsive drug delivery and magnetic resonance imaging,” Biomaterials, vol. 60, pp. 111–120, 2015. View at Publisher · View at Google Scholar · View at Scopus
  93. M.-H. Chan and H.-M. Lin, “Preparation and identification of multifunctional mesoporous silica nanoparticles for in vitro and in vivo dual-mode imaging, theranostics, and targeted tracking,” Biomaterials, vol. 46, pp. 149–158, 2015. View at Publisher · View at Google Scholar · View at Scopus
  94. K. O. Alfarouk, C.-M. Stock, S. Taylor et al., “Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp,” Cancer Cell International, vol. 15, article 71, 2015. View at Publisher · View at Google Scholar · View at Scopus
  95. S. Chen, Z. Wang, Y. Huang et al., “Ginseng and anticancer drug combination to improve cancer chemotherapy: a critical review,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 168940, 13 pages, 2014. View at Publisher · View at Google Scholar
  96. Y. Gao, Y. Chen, X. Ji et al., “Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles,” ACS Nano, vol. 5, no. 12, pp. 9788–9798, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. Y. Chen, Q. Yin, X. Ji et al., “Manganese oxide-based multifunctionalized mesoporous silica nanoparticles for pH-responsive MRI, ultrasonography and circumvention of MDR in cancer cells,” Biomaterials, vol. 33, no. 29, pp. 7126–7137, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. W. C. Zamboni, V. Torchilin, A. K. Patri et al., “Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance,” Clinical Cancer Research, vol. 18, no. 12, pp. 3229–3241, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. B. Li, H. Xu, Z. Li et al., “Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies,” International Journal of Nanomedicine, vol. 7, pp. 187–197, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. W. Jiang, B. Y. S. Kim, J. T. Rutka, and W. C. W. Chan, “Nanoparticle-mediated cellular response is size-dependent,” Nature Nanotechnology, vol. 3, no. 3, pp. 145–150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. W. Punfa, S. Yodkeeree, P. Pitchakarn, C. Ampasavate, and P. Limtrakul, “Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells,” Acta Pharmacologica Sinica, vol. 33, no. 6, pp. 823–831, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. A. S. Gonçalves, A. S. Macedo, and E. B. Souto, “Therapeutic nanosystems for oncology nanomedicine,” Clinical and Translational Oncology, vol. 14, no. 12, pp. 883–890, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. T. Nabekura, “Overcoming multidrug resistance in human cancer cells by natural compounds,” Toxins, vol. 2, no. 6, pp. 1207–1224, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. A. M. Chen, M. Zhang, D. Wei et al., “Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells,” Small, vol. 5, no. 23, pp. 2673–2677, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. C. E. Ashley, E. C. Carnes, G. K. Phillips et al., “The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers,” Nature Materials, vol. 10, no. 6, p. 476, 2011, Erratum to document cited in CA155:021668. View at Google Scholar
  106. A. M. Calcagno, C. D. Salcido, J.-P. Gillet et al., “Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics,” Journal of the National Cancer Institute, vol. 102, no. 21, pp. 1637–1652, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. J. W. Cain, R. S. Hauptschein, J. K. Stewart, T. Bagci, G. G. Sahagian, and D. G. Jay, “Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology,” Molecular Cancer Research, vol. 9, no. 5, pp. 637–647, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Wang, J. Huang, X. Wang et al., “The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel,” Biomaterials, vol. 34, no. 31, pp. 7662–7673, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. X. Wang, Y. Liu, S. Wang et al., “CD44-engineered mesoporous silica nanoparticles for overcoming multidrug resistance in breast cancer,” Applied Surface Science, vol. 332, pp. 308–317, 2015. View at Publisher · View at Google Scholar · View at Scopus
  110. Q. Yin, J. Shen, Z. Zhang, H. Yu, and Y. Li, “Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor,” Advanced Drug Delivery Reviews, vol. 65, no. 13-14, pp. 1699–1715, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. Q. He, Y. Gao, L. Zhang et al., “A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance,” Biomaterials, vol. 32, no. 30, pp. 7711–7720, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. C.-H. Lee, S. Cheng, I. Huang et al., “Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics,” Angewandte Chemie—International Edition, vol. 49, no. 44, pp. 8214–8219, 2010. View at Publisher · View at Google Scholar
  113. X. Zhang, F. Li, S. Guo et al., “Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells,” Biomaterials, vol. 35, no. 11, pp. 3650–3665, 2014. View at Publisher · View at Google Scholar · View at Scopus
  114. L. Xiang, P. Su, S. Xia et al., “ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma,” Diagnostic Pathology, vol. 6, article 90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. D. Damiani, M. Tiribelli, A. Michelutti et al., “Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients,” Leukemia Research, vol. 34, no. 7, pp. 942–945, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. S. H. Lee, H. Kim, J.-H. Hwang et al., “Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients,” Pathology International, vol. 62, no. 3, pp. 167–175, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. C. H. C. Sukowati, N. Rosso, D. Pascut et al., “Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma,” BMC Gastroenterology, vol. 12, article 160, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. Y. Zhao, D. Y. Alakhova, J. O. Kim, T. K. Bronich, and A. V. Kabanov, “A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer,” Journal of Controlled Release, vol. 168, no. 1, pp. 61–69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  119. E. V. Batrakova, S. Li, A. M. Brynskikh et al., “Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers,” Journal of Controlled Release, vol. 143, no. 3, pp. 290–301, 2010. View at Publisher · View at Google Scholar · View at Scopus
  120. T. Yamagata, M. Morishita, H. Kusuhara, K. Takayama, H. Benameur, and Y. Sugiyama, “Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients,” International Journal of Pharmaceutics, vol. 370, no. 1-2, pp. 216–219, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. L. Pan, J. Liu, Q. He, L. Wang, and J. Shi, “Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles,” Biomaterials, vol. 34, no. 11, pp. 2719–2730, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. L. Jia, Z. Li, J. Shen et al., “Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance,” International Journal of Pharmaceutics, vol. 489, no. 1-2, pp. 318–330, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. N. Han, Q. Zhao, L. Wan et al., “Hybrid lipid-capped mesoporous silica for stimuli-responsive drug release and overcoming multidrug resistance,” ACS Applied Materials and Interfaces, vol. 7, no. 5, pp. 3342–3351, 2015. View at Publisher · View at Google Scholar · View at Scopus
  124. D. Spano, C. Heck, P. de Antonellis, G. Christofori, and M. Zollo, “Molecular networks that regulate cancer metastasis,” Seminars in Cancer Biology, vol. 22, no. 3, pp. 234–249, 2012. View at Publisher · View at Google Scholar · View at Scopus
  125. Q. He, S. Guo, Z. Qian, and X. Chen, “Development of individualized anti-metastasis strategies by engineering nanomedicines,” Chemical Society Reviews, vol. 44, no. 17, pp. 6258–6286, 2015. View at Publisher · View at Google Scholar · View at Scopus
  126. Y. Chen, P. Xu, H. Chen et al., “Colloidal HPMO nanoparticles: silica-etching chemistry tailoring, topological transformation, and nano-biomedical applications,” Advanced Materials, vol. 25, no. 22, pp. 3100–3105, 2013. View at Publisher · View at Google Scholar · View at Scopus
  127. Y. Chen, H. Gu, D. S.-Z. Zhang, F. Li, T. Liu, and W. Xia, “Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier,” Biomaterials, vol. 35, no. 38, pp. 10058–10069, 2014. View at Publisher · View at Google Scholar · View at Scopus
  128. M. Egeblad and Z. Werb, “New functions for the matrix metalloproteinases in cancer progression,” Nature Reviews Cancer, vol. 2, no. 3, pp. 161–174, 2002. View at Publisher · View at Google Scholar · View at Scopus
  129. S. H. van Rijt, D. A. Bölükbas, C. Argyo et al., “Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors,” ACS Nano, vol. 9, no. 3, pp. 2377–2389, 2015. View at Publisher · View at Google Scholar · View at Scopus
  130. R. Roy, J. Yang, and M. A. Moses, “Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer,” Journal of Clinical Oncology, vol. 27, no. 31, pp. 5287–5297, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. D. Castanotto and J. J. Rossi, “The promises and pitfalls of RNA-interference-based therapeutics,” Nature, vol. 457, no. 7228, pp. 426–433, 2009. View at Publisher · View at Google Scholar · View at Scopus
  132. Y. Chen, X. Zhu, X. Zhang, B. Liu, and L. Huang, “Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy,” Molecular Therapy, vol. 18, no. 9, pp. 1650–1656, 2010. View at Publisher · View at Google Scholar · View at Scopus
  133. M. Potente, H. Gerhardt, and P. Carmeliet, “Basic and therapeutic aspects of angiogenesis,” Cell, vol. 146, no. 6, pp. 873–887, 2011. View at Publisher · View at Google Scholar · View at Scopus
  134. Y. Ohta, Y. Endo, M. Tanaka et al., “Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer,” Clinical Cancer Research, vol. 2, no. 8, pp. 1411–1416, 1996. View at Google Scholar · View at Scopus
  135. D. Bumcrot, M. Manoharan, V. Koteliansky, and D. W. Y. Sah, “RNAi therapeutics: a potential new class of pharmaceutical drugs,” Nature Chemical Biology, vol. 2, no. 12, pp. 711–719, 2006. View at Publisher · View at Google Scholar · View at Scopus
  136. X. Liu, A. Situ, Y. Kang et al., “Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer,” ACS Nano, vol. 10, no. 2, pp. 2702–2715, 2016. View at Publisher · View at Google Scholar